OCC 20.9% 66.5¢ orthocell limited

Reminder - J&J ATI Rotator Cuff clinical trial update coming soon, page-118

  1. 7,728 Posts.
    lightbulb Created with Sketch. 6991
    https://scitechdaily.com/safety-of-stem-cell-therapy-for-chronic-knee-pain-confirmed-in-new-study/

    Whilst I personally believe cell proliferation and regeneration from Chondrocytes superior to Mesenchymal stem-cells (though a mix having obvious benefits) a study in Japan showing that

    "The results showed that five years after transplantation, osteoarthritis-related tears to the knee meniscus had healed and, just as importantly, none of the patients experienced any serious side effects from the treatment. The meniscus is a crescent-shaped cartilage in the knee joint that plays a role in shock absorption. Age-related damage to the meniscus often leads to the progression of osteoarthritis of the knee."

    This is an autologous stem-cell therapy trial from five years with obvious direct comparison to OCC's ACI treatment. Stem-cells work when properly administered, we all know that, but another autologous trial having a clear efficacy result another indication of likely success in OCC's forthcoming ATI trial.
 
watchlist Created with Sketch. Add OCC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.